{
  "symbol": "JNJ",
  "year": 2023,
  "Period": "Y2023",
  "report_type": "K10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1617,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.159
  },
  "top_positive": [
    {
      "sent": "FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Index to Audited Consolidated Financial Statements 40 Consolidated Balance Sheets 41 Consolidated Statements of Earnings 42 Consolidated Statements of Comprehensive Income 43 Consolidated Statements of Equity 44 Consolidated Statements of Cash Flows 46 Notes to Consolidated Financial Statements 103 Report of Independent Registered Public Accounting Firm (PCAOB ID 238 ) 106 Management\u2019s Report on Internal Control Over Financial Reporting 39 JOHNSON\u00a0& JOHNSON AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS At January\u00a01, 2023 and January\u00a02, 2022 (Dollars in Millions Except Share and Per Share Amounts) (Note\u00a01) 2022 2021 Assets Current assets Cash and cash equivalents (Notes\u00a01 and 2) $ 14,127 14,487 Marketable securities (Notes\u00a01 and 2) 9,392 17,121 Accounts receivable trade, less allowances for doubtful accounts $ 203 (2021, $ 230 ) 16,160 15,283 Inventories (Notes\u00a01 and 3) 12,483 10,387 Prepaid expenses and other receivables 3,132 3,701 Total current assets 55,294 60,979 Property, plant and equipment, net (Notes\u00a01 and 4) 19,803 18,962 Intangible assets, net (Notes\u00a01 and 5) 48,325 46,392 Goodwill (Notes\u00a01 and 5) 45,231 35,246 Deferred taxes on income (Note 8) 9,123 10,223 Other assets 9,602 10,216 Total assets $ 187,378 182,018 Liabilities and Shareholders\u2019 Equity Current liabilities Loans and notes payable (Note\u00a07) $ 12,771 3,766 Accounts payable 11,703 11,055 Accrued liabilities 11,456 13,612 Accrued rebates, returns and promotions 14,417 12,095 Accrued compensation and employee related obligations 3,328 3,586 Accrued taxes on income (Note 8) 2,127 1,112 Total current liabilities 55,802 45,226 Long-term debt (Note\u00a07) 26,888 29,985 Deferred taxes on income (Note 8) 6,374 7,487 Employee related obligations (Notes\u00a09 and 10) 6,767 8,898 Long-term taxes payable (Note 1) 4,306 5,713 Other liabilities 10,437 10,686 Total liabilities 110,574 107,995 Commitments and Contingencies (Note 19) Shareholders\u2019 equity Preferred stock\u00a0\u2014 without par value (authorized and unissued 2,000,000 shares) \u2014 \u2014 Common stock\u00a0\u2014 par value $ 1.00 per share (Note\u00a012) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) 3,120 3,120 Accumulated other comprehensive income (loss) (Note\u00a013) ( 12,967 ) ( 13,058 ) Retained earnings 128,345 123,060 118,498 113,122 Less: common stock held in treasury, at cost (Note\u00a012) ( 506,246,000 shares and 490,878,000 shares) 41,694 39,099 Total shareholders\u2019 equity 76,804 74,023 Total liabilities and shareholders\u2019 equity $ 187,378 182,018 See Notes to Consolidated Financial Statements 40 JOHNSON\u00a0& JOHNSON AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF EARNINGS (Dollars and Shares in Millions Except Per Share Amounts) (Note\u00a01) 2022 2021 2020 Sales to customers $ 94,943 93,775 82,584 Cost of products sold 31,089 29,855 28,427 Gross profit 63,854 63,920 54,157 Selling, marketing and administrative expenses 24,765 24,659 22,084 Research and development expense 14,603 14,714 12,159 In-process research and development (Note 5) 783 900 181 Interest income ( 490 ) ( 53 ) ( 111 ) Interest expense, net of portion capitalized (Note\u00a04) 276 183 201 Other (income) expense, net 1,871 489 2,899 Restructuring (Note 20) 321 252 247 Earnings before provision for taxes on income 21,725 22,776 16,497 Provision for taxes on income (Note\u00a08) 3,784 1,898 1,783 Net earnings $ 17,941 20,878 14,714 Net earnings per share (Notes 1 and 15) Basic $ 6.83 7.93 5.59 Diluted $ 6.73 7.81 5.51 Average shares outstanding (Notes 1 and 15) Basic 2,625.2 2,632.1 2,632.8 Diluted 2,663.9 2,674.0 2,670.7 See Notes to Consolidated Financial Statements 41 JOHNSON & JOHNSON AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Dollars in Millions) (Note\u00a01) 2022 2021 2020 Net earnings $ 17,941 20,878 14,714 Other comprehensive income (loss), net of tax Foreign currency translation ( 1,796 ) ( 1,079 ) ( 233 ) Securities: Unrealized holding gain (loss) arising during period ( 24 ) ( 4 ) 1 Reclassifications to earnings \u2014 \u2014 \u2014 Net change ( 24 ) ( 4 ) 1 Employee benefit plans: Prior service credit (cost), net of amortization ( 160 ) ( 169 ) 1,298 Gain (loss), net of amortization 1,854 4,318 ( 1,135 ) Effect of exchange rates 111 106 ( 229 ) Net change 1,805 4,255 ( 66 ) Derivatives & hedges: Unrealized gain (loss) arising during period 454 ( 199 ) 1,000 Reclassifications to earnings ( 348 ) ( 789 ) ( 53 ) Net change 106 ( 988 ) 947 Other comprehensive income (loss) 91 2,184 649 Comprehensive income $ 18,032 23,062 15,363 The tax effects in other comprehensive income for the fiscal years 2022, 2021 and 2020 respectively: Foreign Currency Translation; $ 460 million, $ 346 million and $ 536 million; Securities: $ 6 million and $ 1 million in 2022 and 2021, Employee Benefit Plans: $ 461 million, $ 1,198 million and $ 21 million, Derivatives & Hedges: $ 30 million, $ 263 million and $ 252 million.",
      "score": 0.9967
    },
    {
      "sent": "Risks and uncertainties include, but are not limited to: Risks Related to Product Development, Market Success and Competition \u2022 Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company\u2019s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success; \u2022 Challenges to the Company\u2019s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets; \u2022 The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses; \u2022 Increasingly aggressive and frequent challenges to the Company\u2019s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected; \u2022 Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence; \u2022 Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies; \u2022 Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and \u2022 Allegations that the Company\u2019s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company\u2019s ability to sell the products in question and require the payment of money damages and future royalties.",
      "score": 0.9962
    },
    {
      "sent": "The Company\u2019s human capital management strategy is built on three fundamental focus areas: \u2022 Attracting and recruiting the best talent \u2022 Developing and retaining talent \u2022 Empowering and inspiring talent Underpinning these focus areas are ongoing efforts to cultivate and foster a culture built on diversity, equity and inclusion (DEI), innovation, health, well-being and safety, where the Company's employees are encouraged to succeed both professionally and personally while helping the Company achieve its business goals.",
      "score": 0.9831
    }
  ],
  "top_negative": [
    {
      "sent": "Key products in the Pharmaceutical segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis and active polyarticular juvenile idiopathic arthritis (pJIA) in people 2 years of age and older; STELARA (ustekinumab), a treatment for adults and children with moderate to severe plaque psoriasis, for adults with active psoriatic arthritis, for adults with moderately to severely active Crohn's disease and treatment of moderately to severely active ulcerative colitis; TREMFYA (guselkumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; EDURANT (rilpivirine), PREZISTA (darunavir) and PREZCOBIX/REZOLSTA (darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral products and SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily single tablet regimen for the treatment of HIV; CONCERTA (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA SUSTENNA/XEPLION (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA/TREVICTA (paliperidone palmitate), for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA for at least four months; RISPERDAL CONSTA (risperidone long-acting injection), for the treatment of schizophrenia and the maintenance treatment of Bipolar 1 Disorder in adults; ZYTIGA 1 (abiraterone acetate), a treatment for patients with prostate cancer; ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer; IMBRUVICA (ibrutinib), a treatment for certain B-cell malignancies, or blood cancers and chronic graft versus host disease; DARZALEX (daratumumab), a treatment for multiple myeloma; DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a treatment for multiple myeloma and light chain (AL) Amyloidosis; XARELTO (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and reduction of risk of recurrence of DVT and PE to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) and peripheral artery disease (PAD), for the treatment and secondary prevention of thromboembolism in pediatric patients, and for thromboprophylaxis in pediatric patients following the Fontan procedure; INVOKANA (canagliflozin), for the treatment of adults with type 2 diabetes; INVOKAMET/VOKANAMET (canagliflozin/metformin HCl), a combination therapy of fixed doses of canagliflozin and metformin hydrochloride for the treatment of adults with type 2 diabetes; and INVOKAMET XR (canagliflozin/metformin hydrochloride extended-release), a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release, for the treatment of adults with type 2 diabetes; OPSUMIT (macitentan) as monotherapy or in combination, indicated for the long-term treatment of pulmonary arterial hypertension (PAH); UPTRAVI (selexipag), the only approved oral and intravenous, selective IP receptor agonist targeting a prostacyclin pathway in PAH.",
      "score": -0.8934
    },
    {
      "sent": "Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks.",
      "score": -0.8658
    },
    {
      "sent": "The Russia-Ukraine War, and actions taken in response to the Russia-Ukraine War, could adversely affect our business, results of operations or financial condition.",
      "score": -0.8625
    }
  ],
  "forward_snippets": [
    "Additionally, we expect continued scrutiny on drug pricing and government price reporting from Congress, agencies, and other bodies at the federal and state levels.",
    "Employees worldwide must adhere to the Company\u2019s Code of Business Conduct which sets basic requirements and serves as a foundation for the Company policies, procedures and guidelines, all of which provide additional guidance on expected employee behaviors in every market where it operates.",
    "The Company's objective is to foster a learning culture that helps shape each person\u2019s unique career path while creating a robust pipeline of talent to deliver on the Company\u2019s long-term strategies.",
    "Employees worldwide must adhere to the Company\u2019s Code of Business Conduct which sets basic requirements and serves as a foundation for the Company policies, procedures and guidelines, all of which provide additional guidance on expected employee behaviors in every market where it operates.",
    "The Company's objective is to foster a learning culture that helps shape each person\u2019s unique career path while creating a robust pipeline of talent to deliver on the Company\u2019s long-term strategies."
  ],
  "curated_text": "Symbol: JNJ. Year: 2023. Period: Y2023. ReportType: K10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Index to Audited Consolidated Financial Statements 40 Consolidated Balance Sheets 41 Consolidated Statements of Earnings 42 Consolidated Statements of Comprehensive Income 43 Consolidated Statements of Equity 44 Consolidated Statements of Cash Flows 46 Notes to Consolidated Financial Statements 103 Report of Independent Registered Public Accounting Firm (PCAOB ID 238 ) 106 Management\u2019s Report on Internal Control Over Financial Reporting 39 JOHNSON\u00a0& JOHNSON AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS At January\u00a01, 2023 and January\u00a02, 2022 (Dollars in Millions Except Share and Per Share Amounts) (Note\u00a01) 2022 2021 Assets Current assets Cash and cash equivalents (Notes\u00a01 and 2) $ 14,127 14,487 Marketable securities (Notes\u00a01 and 2) 9,392 17,121 Accounts receivable trade, less allowances for doubtful accounts $ 203 (2021, $ 230 ) 16,160 15,283 Inventories (Notes\u00a01 and 3) 12,483 10,387 Prepaid expenses and other receivables 3,132 3,701 Total current assets 55,294 60,979 Property, plant and equipment, net (Notes\u00a01 and 4) 19,803 18,962 Intangible assets, net (Notes\u00a01 and 5) 48,325 46,392 Goodwill (Notes\u00a01 and 5) 45,231 35,246 Deferred taxes on income (Note 8) 9,123 10,223 Other assets 9,602 10,216 Total assets $ 187,378 182,018 Liabilities and Shareholders\u2019 Equity Current liabilities Loans and notes payable (Note\u00a07) $ 12,771 3,766 Accounts payable 11,703 11,055 Accrued liabilities 11,456 13,612 Accrued rebates, returns and promotions 14,417 12,095 Accrued compensation and employee related obligations 3,328 3,586 Accrued taxes on income (Note 8) 2,127 1,112 Total current liabilities 55,802 45,226 Long-term debt (Note\u00a07) 26,888 29,985 Deferred taxes on income (Note 8) 6,374 7,487 Employee related obligations (Notes\u00a09 and 10) 6,767 8,898 Long-term taxes payable (Note 1) 4,306 5,713 Other liabilities 10,437 10,686 Total liabilities 110,574 107,995 Commitments and Contingencies (Note 19) Shareholders\u2019 equity Preferred stock\u00a0\u2014 without par value (authorized and unissued 2,000,000 shares) \u2014 \u2014 Common stock\u00a0\u2014 par value $ 1.00 per share (Note\u00a012) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares) 3,120 3,120 Accumulated other comprehensive income (loss) (Note\u00a013) ( 12,967 ) ( 13,058 ) Retained earnings 128,345 123,060 118,498 113,122 Less: common stock held in treasury, at cost (Note\u00a012) ( 506,246,000 shares and 490,878,000 shares) 41,694 39,099 Total shareholders\u2019 equity 76,804 74,023 Total liabilities and shareholders\u2019 equity $ 187,378 182,018 See Notes to Consolidated Financial Statements 40 JOHNSON\u00a0& JOHNSON AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF EARNINGS (Dollars and Shares in Millions Except Per Share Amounts) (Note\u00a01) 2022 2021 2020 Sales to customers $ 94,943 93,775 82,584 Cost of products sold 31,089 29,855 28,427 Gross profit 63,854 63,920 54,157 Selling, marketing and administrative expenses 24,765 24,659 22,084 Research and development expense 14,603 14,714 12,159 In-process research and development (Note 5) 783 900 181 Interest income ( 490 ) ( 53 ) ( 111 ) Interest expense, net of portion capitalized (Note\u00a04) 276 183 201 Other (income) expense, net 1,871 489 2,899 Restructuring (Note 20) 321 252 247 Earnings before provision for taxes on income 21,725 22,776 16,497 Provision for taxes on income (Note\u00a08) 3,784 1,898 1,783 Net earnings $ 17,941 20,878 14,714 Net earnings per share (Notes 1 and 15) Basic $ 6.83 7.93 5.59 Diluted $ 6.73 7.81 5.51 Average shares outstanding (Notes 1 and 15) Basic 2,625.2 2,632.1 2,632.8 Diluted 2,663.9 2,674.0 2,670.7 See Notes to Consolidated Financial Statements 41 JOHNSON & JOHNSON AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Dollars in Millions) (Note\u00a01) 2022 2021 2020 Net earnings $ 17,941 20,878 14,714 Other comprehensive income (loss), net of tax Foreign currency translation ( 1,796 ) ( 1,079 ) ( 233 ) Securities: Unrealized holding gain (loss) arising during period ( 24 ) ( 4 ) 1 Reclassifications to earnings \u2014 \u2014 \u2014 Net change ( 24 ) ( 4 ) 1 Employee benefit plans: Prior service credit (cost), net of amortization ( 160 ) ( 169 ) 1,298 Gain (loss), net of amortization 1,854 4,318 ( 1,135 ) Effect of exchange rates 111 106 ( 229 ) Net change 1,805 4,255 ( 66 ) Derivatives & hedges: Unrealized gain (loss) arising during period 454 ( 199 ) 1,000 Reclassifications to earnings ( 348 ) ( 789 ) ( 53 ) Net change 106 ( 988 ) 947 Other comprehensive income (loss) 91 2,184 649 Comprehensive income $ 18,032 23,062 15,363 The tax effects in other comprehensive income for the fiscal years 2022, 2021 and 2020 respectively: Foreign Currency Translation; $ 460 million, $ 346 million and $ 536 million; Securities: $ 6 million and $ 1 million in 2022 and 2021, Employee Benefit Plans: $ 461 million, $ 1,198 million and $ 21 million, Derivatives & Hedges: $ 30 million, $ 263 million and $ 252 million. Risks and uncertainties include, but are not limited to: Risks Related to Product Development, Market Success and Competition \u2022 Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company\u2019s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success; \u2022 Challenges to the Company\u2019s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets; \u2022 The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses; \u2022 Increasingly aggressive and frequent challenges to the Company\u2019s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected; \u2022 Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence; \u2022 Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies; \u2022 Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and \u2022 Allegations that the Company\u2019s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company\u2019s ability to sell the products in question and require the payment of money damages and future royalties. The Company\u2019s human capital management strategy is built on three fundamental focus areas: \u2022 Attracting and recruiting the best talent \u2022 Developing and retaining talent \u2022 Empowering and inspiring talent Underpinning these focus areas are ongoing efforts to cultivate and foster a culture built on diversity, equity and inclusion (DEI), innovation, health, well-being and safety, where the Company's employees are encouraged to succeed both professionally and personally while helping the Company achieve its business goals. Top negative sentences: Key products in the Pharmaceutical segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis and active polyarticular juvenile idiopathic arthritis (pJIA) in people 2 years of age and older; STELARA (ustekinumab), a treatment for adults and children with moderate to severe plaque psoriasis, for adults with active psoriatic arthritis, for adults with moderately to severely active Crohn's disease and treatment of moderately to severely active ulcerative colitis; TREMFYA (guselkumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; EDURANT (rilpivirine), PREZISTA (darunavir) and PREZCOBIX/REZOLSTA (darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral products and SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily single tablet regimen for the treatment of HIV; CONCERTA (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA SUSTENNA/XEPLION (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA/TREVICTA (paliperidone palmitate), for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA for at least four months; RISPERDAL CONSTA (risperidone long-acting injection), for the treatment of schizophrenia and the maintenance treatment of Bipolar 1 Disorder in adults; ZYTIGA 1 (abiraterone acetate), a treatment for patients with prostate cancer; ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer; IMBRUVICA (ibrutinib), a treatment for certain B-cell malignancies, or blood cancers and chronic graft versus host disease; DARZALEX (daratumumab), a treatment for multiple myeloma; DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a treatment for multiple myeloma and light chain (AL) Amyloidosis; XARELTO (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and reduction of risk of recurrence of DVT and PE to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) and peripheral artery disease (PAD), for the treatment and secondary prevention of thromboembolism in pediatric patients, and for thromboprophylaxis in pediatric patients following the Fontan procedure; INVOKANA (canagliflozin), for the treatment of adults with type 2 diabetes; INVOKAMET/VOKANAMET (canagliflozin/metformin HCl), a combination therapy of fixed doses of canagliflozin and metformin hydrochloride for the treatment of adults with type 2 diabetes; and INVOKAMET XR (canagliflozin/metformin hydrochloride extended-release), a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release, for the treatment of adults with type 2 diabetes; OPSUMIT (macitentan) as monotherapy or in combination, indicated for the long-term treatment of pulmonary arterial hypertension (PAH); UPTRAVI (selexipag), the only approved oral and intravenous, selective IP receptor agonist targeting a prostacyclin pathway in PAH. Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. The Russia-Ukraine War, and actions taken in response to the Russia-Ukraine War, could adversely affect our business, results of operations or financial condition. Forward-looking snippets: Additionally, we expect continued scrutiny on drug pricing and government price reporting from Congress, agencies, and other bodies at the federal and state levels. Employees worldwide must adhere to the Company\u2019s Code of Business Conduct which sets basic requirements and serves as a foundation for the Company policies, procedures and guidelines, all of which provide additional guidance on expected employee behaviors in every market where it operates. The Company's objective is to foster a learning culture that helps shape each person\u2019s unique career path while creating a robust pipeline of talent to deliver on the Company\u2019s long-term strategies. Employees worldwide must adhere to the Company\u2019s Code of Business Conduct which sets basic requirements and serves as a foundation for the Company policies, procedures and guidelines, all of which provide additional guidance on expected employee behaviors in every market where it operates. The Company's objective is to foster a learning culture that helps shape each person\u2019s unique career path while creating a robust pipeline of talent to deliver on the Company\u2019s long-term strategies."
}